CSI Market
Sign In | Register

Biospecifics Technologies (BSTC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BSTC Annual Cash Flow →
The data below summarizes Biospecifics Technologies's cash flow activity from Sep 30 2019 to Sep 30 2020, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2020)
9 Months 		(Jun 30 2020) (Mar 31 2020) (Dec 31 2019) (Sep 30 2019)
Operating Activities
Income10.00
Depreciation & amortization0.07
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.17
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Patent Expense-
Extinguishment Of Accrued Liabilities-
Operating Lease Right Of Use Asset Amortization Expense-
Noncash Lease Expense0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable5.12
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.41
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-1.18
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.79
Discontinued operations0.00
Net Cash flow from Operating Activities16.44
Investing Activities
Capital Expenditures-0.07
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities87.28
Payments to Acquire Marketable Securities-105.43
Real Estate Investments0.00
Payment For Royalty Buy Down-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-18.22
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.35
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-5.00
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents5.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.35
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow16.37
Total Cash Flow-2.13
4 historic quarters locked

Sign in to unlock the full Biospecifics Technologies cash flow history.

Sign In Create Free Account

About BSTC Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.